Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy

Progress in Molecular Biology and Translational Science

Volumn 110, Issue , 2012, Pages 289-314

  Morandell, Sandra ^a   Yaffe, Michael B ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cell cycle arrest; Cell cycle checkpoint; DNA damage signaling; p53; Synthetic lethality; Targeted cancer therapy

Indexed keywords

EID: 84862999019     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387665-2.00011-0     Document Type: Chapter

References (146)

1. R.D. Kennedy, and A.D. D'Andrea DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes J Clin Oncol 24 2006 3799 3808 (Pubitemid 46622318)
2. M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323 (Pubitemid 39551659)
3. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
4. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
5. W.C. Hahn, and R.A. Weinberg Modelling the molecular circuitry of cancer Nat Rev Cancer 2 2002 331 341 (Pubitemid 37328946)
6. S. Jones, X. Zhang, D.W. Parsons, J.C. Lin, R.J. Leary, and P. Angenendt Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
7. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310 (Pubitemid 46763022)
8. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
9. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
10. A.D. Cox, and C.J. Der Ras family signaling: therapeutic targeting Cancer Biol Ther 1 2002 599 606
11. G. Fritz Targeting the mevalonate pathway for improved anticancer therapy Curr Cancer Drug Targets 9 2009 626 638
12. T. Frebourg, and S.H. Friend Cancer risks from germline p53 mutations J Clin Invest 90 1992 1637 1641
13. M.F. Lavin, and Y. Shiloh The genetic defect in ataxia-telangiectasia Annu Rev Immunol 15 1997 177 202 (Pubitemid 27169279)
14. A.R. Lehmann DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy Biochimie 85 2003 1101 1111 (Pubitemid 38142364)
15. M. O'Driscoll, V.L. Ruiz-Perez, C.G. Woods, P.A. Jeggo, and J.A. Goodship A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome Nat Genet 33 2003 497 501 (Pubitemid 36390012)
16. Y. Shiloh ATM and related protein kinases: safeguarding genome integrity Nat Rev Cancer 3 2003 155 168 (Pubitemid 37328868)
17. A.M. Taylor, A. Groom, and P.J. Byrd Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis DNA Repair (Amst) 3 2004 1219 1225 (Pubitemid 38997965)
18. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, and K. Zieger DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 2005 864 870 (Pubitemid 40558993)
19. H. Nevanlinna, and J. Bartek The CHEK2 gene and inherited breast cancer susceptibility Oncogene 25 2006 5912 5919 (Pubitemid 44453447)
20. J.D. Fackenthal, and O.I. Olopade Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations Nat Rev Cancer 7 2007 937 948 (Pubitemid 350165853)
21. B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433 439
22. J. Bartek, and J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 3 2003 421 429 (Pubitemid 38340288)
23. J.W. Harper, and S.J. Elledge The DNA damage response: ten years after Mol Cell 28 2007 739 745 (Pubitemid 350217064)
24. H.C. Reinhardt, and M.B. Yaffe Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2 Curr Opin Cell Biol 21 2009 245 255
25. I.A. Manke, A. Nguyen, D. Lim, M.Q. Stewart, A.E. Elia, and M.B. Yaffe MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation Mol Cell 17 2005 37 48 (Pubitemid 40075363)
26. H.C. Reinhardt, A.S. Aslanian, J.A. Lees, and M.B. Yaffe p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 11 2007 175 189 (Pubitemid 46209849)
27. H.C. Reinhardt, P. Hasskamp, I. Schmedding, S. Morandell, M.A. van Vugt, and X. Wang DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization Mol Cell 40 2010 34 49
28. S.L. Harris, and A.J. Levine The p53 pathway: positive and negative feedback loops Oncogene 24 2005 2899 2908 (Pubitemid 40638098)
29. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
30. J.S. Fridman, and S.W. Lowe Control of apoptosis by p53 Oncogene 22 2003 9030 9040 (Pubitemid 38121703)
31. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat Rev Cancer 2 2002 594 604 (Pubitemid 37328926)
32. M. Donzelli, and G.F. Draetta Regulating mammalian checkpoints through Cdc25 inactivation EMBO Rep 4 2003 671 677 (Pubitemid 36974751)
33. J. Jin, T. Shirogane, L. Xu, G. Nalepa, J. Qin, and S.J. Elledge SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase Genes Dev 17 2003 3062 3074 (Pubitemid 38040770)
34. C.S. Sorensen, R.G. Syljuasen, J. Falck, T. Schroeder, L. Ronnstrand, and K.K. Khanna Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Cancer Cell 3 2003 247 258 (Pubitemid 37443880)
35. Y. Zeng, and H. Piwnica-Worms DNA damage and replication checkpoints in fission yeast require nuclear exclusion of the Cdc25 phosphatase via 14-3-3 binding Mol Cell Biol 19 1999 7410 7419 (Pubitemid 29493404)
36. A.K. Gardino, and M.B. Yaffe 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis Semin Cell Dev Biol 22 2011 688 695
37. H.C. Reinhardt, H. Jiang, M.T. Hemann, and M.B. Yaffe Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle 8 2009 3112 3119
38. T. Dobzhansky Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura Genetics 31 1946 269 290
39. J.L. Hartman, B. Garvik, and L. Hartwell Principles for the buffering of genetic variation Science 291 2001 1001 1004
40. W.G. Kaelin Jr. The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698 (Pubitemid 41486362)
41. L.H. Hartwell, P. Szankasi, C.J. Roberts, A.W. Murray, and S.H. Friend Integrating genetic approaches into the discovery of anticancer drugs Science 278 1997 1064 1068 (Pubitemid 27517876)
42. A. Bommi-Reddy, I. Almeciga, J. Sawyer, C. Geisen, W. Li, and E. Harlow Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen Proc Natl Acad Sci U S A 105 2008 16484 16489
43. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917 (Pubitemid 40559005)
44. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
45. J.H. Hoeijmakers Genome maintenance mechanisms for preventing cancer Nature 411 2001 366 374 (Pubitemid 32467046)
46. S.A. Martin, C.J. Lord, and A. Ashworth DNA repair deficiency as a therapeutic target in cancer Curr Opin Genet Dev 18 2008 80 86 (Pubitemid 351694447)
47. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
48. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
49. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, and C. Gourley Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
50. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, and J.N. Weitzel Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
51. S.K. Sandhu, T.A. Yap, and J.S. de Bono Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur J Cancer 46 2010 9 20
52. J.D. Iglehart, and D.P. Silver Synthetic lethality - a new direction in cancer-drug development N Engl J Med 361 2009 189 191
53. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 2008 3785 3790
54. ClinicalTrials.gov, A service of the U.S. National Institute of Health; (n.d.); retrieved from www.clinicaltrials.gov
55. Z.Q. Wang, B. Auer, L. Stingl, H. Berghammer, D. Haidacher, and M. Schweiger Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease Genes Dev 9 1995 509 520
56. W.M. Tong, Y.G. Yang, W.H. Cao, D. Galendo, L. Frappart, and Y. Shen Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice Oncogene 26 2007 3857 3867 (Pubitemid 46878132)
57. S.L. Edwards, R. Brough, C.J. Lord, R. Natrajan, R. Vatcheva, and D.A. Levine Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115 (Pubitemid 351317441)
58. W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, J. Higgins, and C. Friedman Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 2008 1116 1120 (Pubitemid 351317449)
59. A. Maya-Mendoza, E. Petermann, D.A. Gillespie, K.W. Caldecott, and D.A. Jackson Chk1 regulates the density of active replication origins during the vertebrate S phase EMBO J 26 2007 2719 2731 (Pubitemid 46884282)
60. K.A. Cimprich, and D. Cortez ATR: an essential regulator of genome integrity Nat Rev Mol Cell Biol 9 2008 616 627 (Pubitemid 352032926)
61. R. Boutros, V. Lobjois, and B. Ducommun CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 7 2007 495 507 (Pubitemid 46985396)
62. H. Zhao, J.L. Watkins, and H. Piwnica-Worms Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints Proc Natl Acad Sci U S A 99 2002 14795 14800 (Pubitemid 35334563)
63. E.J. Brown, and D. Baltimore ATR disruption leads to chromosomal fragmentation and early embryonic lethality Genes Dev 14 2000 397 402 (Pubitemid 30131885)
64. Q. Liu, S. Guntuku, X.S. Cui, S. Matsuoka, D. Cortez, and K. Tamai Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint Genes Dev 14 2000 1448 1459 (Pubitemid 30421838)
65. H. Takai, K. Tominaga, N. Motoyama, Y.A. Minamishima, H. Nagahama, and T. Tsukiyama Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice Genes Dev 14 2000 1439 1447 (Pubitemid 30421837)
66. I. Takahashi, E. Kobayashi, H. Nakano, C. Murakata, H. Saitoh, and K. Suzuki Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C J Pharmacol Exp Ther 255 1990 1218 1221
67. P.R. Graves, L. Yu, J.K. Schwarz, J. Gales, E.A. Sausville, and P.M. O'Connor The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 J Biol Chem 275 2000 5600 5605 (Pubitemid 30115197)
68. E.C. Busby, D.F. Leistritz, R.T. Abraham, L.M. Karnitz, and J.N. Sarkaria The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 Cancer Res 60 2000 2108 2112 (Pubitemid 30225168)
69. S. Sato, N. Fujita, and T. Tsuruo Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) Oncogene 21 2002 1727 1738 (Pubitemid 34259036)
70. R.T. Bunch, and A. Eastman Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor Clin Cancer Res 2 1996 791 797 (Pubitemid 26168931)
71. A.A. Levesque, A.A. Fanous, A. Poh, and A. Eastman Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest Mol Cancer Ther 7 2008 252 262 (Pubitemid 351302519)
72. Q. Wang, S. Fan, A. Eastman, P.J. Worland, E.A. Sausville, and P.M. O'Connor UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J Natl Cancer Inst 88 1996 956 965 (Pubitemid 26239383)
73. P.M. Fracasso, K.J. Williams, R.C. Chen, J. Picus, C.X. Ma, and M.J. Ellis A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies Cancer Chemother Pharmacol 67 2011 1225 1237
74. C.X. Ma, J.W. Janetka, and H. Piwnica-Worms Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol Med 17 2011 88 96
75. N. Sangster-Guity, B.H. Conrad, N. Papadopoulos, and F. Bunz ATR mediates cisplatin resistance in a p53 genotype-specific manner Oncogene 30 2011 2526 2533
76. P.J. Hurley, D. Wilsker, and F. Bunz Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation Oncogene 26 2007 2535 2542 (Pubitemid 46632006)
77. G.K. Alderton, H. Joenje, R. Varon, A.D. Borglum, P.A. Jeggo, and M. O'Driscoll Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway Hum Mol Genet 13 2004 3127 3138 (Pubitemid 40045265)
78. D. Wilsker, and F. Bunz Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol Cancer Ther 6 2007 1406 1413 (Pubitemid 46712004)
79. H. Jiang, H.C. Reinhardt, J. Bartkova, J. Tommiska, C. Blomqvist, and H. Nevanlinna The combined status of ATM and p53 link tumor development with therapeutic response Genes Dev 23 2009 1895 1909
80. L.I. Toledo, M. Murga, R. Zur, R. Soria, A. Rodriguez, and S. Martinez A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Nat Struct Mol Biol 18 2011 721 727
81. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, and C. Fritsch Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 2008 1851 1863
82. J.D. Charrier, S.J. Durrant, J.M. Golec, D.P. Kay, R.M. Knegtel, and S. MacCormick Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents J Med Chem 54 2011 2320 2330
83. P.M. Reaper, M.R. Griffiths, J.M. Long, J.D. Charrier, S. Maccormick, and P.A. Charlton Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nat Chem Biol 7 2011 428 430
84. O. Gilad, B.Y. Nabet, R.L. Ragland, D.W. Schoppy, K.D. Smith, and A.C. Durham Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner Cancer Res 70 2010 9693 9702
85. M.H. Lam, Q. Liu, S.J. Elledge, and J.M. Rosen Chk1 is haploinsufficient for multiple functions critical to tumor suppression Cancer Cell 6 2004 45 59 (Pubitemid 38903161)
86. A. Menoyo, H. Alazzouzi, E. Espin, M. Armengol, H. Yamamoto, and S. Schwartz Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability Cancer Res 61 2001 7727 7730 (Pubitemid 33049356)
87. V. Vassileva, A. Millar, L. Briollais, W. Chapman, and B. Bapat Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability Cancer Res 62 2002 4095 4099 (Pubitemid 34791080)
88. K.A. Lewis, J. Bakkum-Gamez, R. Loewen, A.J. French, S.N. Thibodeau, and W.A. Cliby Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers Genes Chromosomes Cancer 46 2007 1061 1068 (Pubitemid 47614540)
89. A. Fedier, M. Schlamminger, V.A. Schwarz, U. Haller, S.B. Howell, and D. Fink Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites Ann Oncol 14 2003 938 945 (Pubitemid 36827211)
90. C. Morrison, E. Sonoda, N. Takao, A. Shinohara, K. Yamamoto, and S. Takeda The controlling role of ATM in homologous recombinational repair of DNA damage EMBO J 19 2000 463 471 (Pubitemid 30072616)
91. M. Kuhne, E. Riballo, N. Rief, K. Rothkamm, P.A. Jeggo, and M. Lobrich A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity Cancer Res 64 2004 500 508 (Pubitemid 38120888)
92. M.E. Dar, T.A. Winters, and T.J. Jorgensen Identification of defective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in ataxia-telangiectasia cells Mutat Res 384 1997 169 179 (Pubitemid 27394242)
93. A.L. Bredemeyer, G.G. Sharma, C.Y. Huang, B.A. Helmink, L.M. Walker, and K.C. Khor ATM stabilizes DNA double-strand-break complexes during V(D)J recombination Nature 442 2006 466 470 (Pubitemid 44264797)
94. E. Riballo, M. Kuhne, N. Rief, A. Doherty, G.C. Smith, and M.J. Recio A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci Mol Cell 16 2004 715 724 (Pubitemid 39586530)
95. S.S. Yuan, H.L. Chang, and E.Y. Lee Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(-/-) and c-Abl(-/-) cells Mutat Res 525 2003 85 92 (Pubitemid 36332260)
96. L.G. DeFazio, R.M. Stansel, J.D. Griffith, and G. Chu Synapsis of DNA ends by DNA-dependent protein kinase EMBO J 21 2002 3192 3200 (Pubitemid 34670402)
97. S.P. Lees-Miller, and K. Meek Repair of DNA double strand breaks by non-homologous end joining Biochimie 85 2003 1161 1173 (Pubitemid 38142369)
98. L. Spagnolo, A. Rivera-Calzada, L.H. Pearl, and O. Llorca Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair Mol Cell 22 2006 511 519 (Pubitemid 43740469)
99. G.C. Smith, and S.P. Jackson The DNA-dependent protein kinase Genes Dev 13 1999 916 934 (Pubitemid 29200976)
100. K.E. Gurley, and C.J. Kemp Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis Curr Biol 11 2001 191 194 (Pubitemid 32152105)
101. V. Lafarga, A. Cuadrado, I. Lopez de Silanes, R. Bengoechea, O. Fernandez-Capetillo, and A.R. Nebreda p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint Mol Cell Biol 29 2009 4341 4351
102. D.V. Bulavin, Y. Higashimoto, I.J. Popoff, W.A. Gaarde, V. Basrur, and O. Potapova Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase Nature 411 2001 102 107 (Pubitemid 32428198)
103. M. Raman, S. Earnest, K. Zhang, Y. Zhao, and M.H. Cobb TAO kinases mediate activation of p38 in response to DNA damage EMBO J 26 2007 2005 2014 (Pubitemid 46625802)
104. Y. Hirose, M. Katayama, D. Stokoe, D.A. Haas-Kogan, M.S. Berger, and R.O. Pieper The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents Mol Cell Biol 23 2003 8306 8315 (Pubitemid 37377519)
105. Y. Hirose, M. Katayama, M.S. Berger, and R.O. Pieper Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide J Neurosurg 100 2004 1060 1065 (Pubitemid 38661619)
106. J.L. Perfettini, R. Nardacci, M. Bourouba, F. Subra, L. Gros, and C. Seror Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia PLoS One 3 2008 e2458
107. J.M. Kyriakis, and J. Avruch Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 81 2001 807 869 (Pubitemid 32267078)
108. L.L. Parker, and H. Piwnica-Worms Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase Science 257 1992 1955 1957
109. R. Rowley, J. Hudson, and P.G. Young The wee1 protein kinase is required for radiation-induced mitotic delay Nature 356 1992 353 355
110. R. Heald, M. McLoughlin, and F. McKeon Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase Cell 74 1993 463 474 (Pubitemid 23244612)
111. J. Lee, A. Kumagai, and W.G. Dunphy Positive regulation of Wee1 by Chk1 and 14-3-3 proteins Mol Biol Cell 12 2001 551 563 (Pubitemid 33052011)
112. Y. Tominaga, C. Li, R.H. Wang, and C.X. Deng Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development Int J Biol Sci 2 2006 161 170 (Pubitemid 43846008)
113. Y. Wang, S.J. Decker, and J. Sebolt-Leopold Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis Cancer Biol Ther 3 2004 305 313 (Pubitemid 41350885)
114. S.E. Mir, P.C. De Witt Hamer, P.M. Krawczyk, L. Balaj, A. Claes, and J.M. Niers In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma Cancer Cell 18 2010 244 257
115. R.L. Panek, G.H. Lu, S.R. Klutchko, B.L. Batley, T.K. Dahring, and J.M. Hamby In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor J Pharmacol Exp Ther 283 1997 1433 1444 (Pubitemid 28016519)
116. Y. Wang, J. Li, R.N. Booher, A. Kraker, T. Lawrence, and W.R. Leopold Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator Cancer Res 61 2001 8211 8217 (Pubitemid 33091614)
117. J. PosthumaDeBoer, T. Wurdinger, H.C. Graat, V.W. van Beusechem, M.N. Helder, and B.J. van Royen WEE1 inhibition sensitizes osteosarcoma to radiotherapy BMC Cancer 11 2011 156
118. P.C. De Witt Hamer, S.E. Mir, D. Noske, C.J. Van Noorden, and T. Wurdinger WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe Clin Cancer Res 17 2011 4200 4207
119. S. Mizuarai, K. Yamanaka, H. Itadani, T. Arai, T. Nishibata, and H. Hirai Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor Mol Cancer 8 2009 34
120. H. Hirai, Y. Iwasawa, M. Okada, T. Arai, T. Nishibata, and M. Kobayashi Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol Cancer Ther 8 2009 2992 3000
121. H. Hirai, T. Arai, M. Okada, T. Nishibata, M. Kobayashi, and N. Sakai MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil Cancer Biol Ther 9 2010 514 522
122. N.V. Rajeshkumar, E. De Oliveira, N. Ottenhof, J. Watters, D. Brooks, and T. Demuth MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts Clin Cancer Res 17 2011 2799 2806
123. S. Leijen, J.H. Beijnen, and J.H. Schellens Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents Curr Clin Pharmacol 5 2010 186 191
124. P. Vichi, F. Coin, J.P. Renaud, W. Vermeulen, J.H. Hoeijmakers, and D. Moras Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP EMBO J 16 1997 7444 7456 (Pubitemid 28010504)
125. D.A. Rockx, R. Mason, A. van Hoffen, M.C. Barton, E. Citterio, and D.B. Bregman UV-induced inhibition of transcription involves repression of transcription initiation and phosphorylation of RNA polymerase II Proc Natl Acad Sci U S A 97 2000 10503 10508
126. K.E. Rieger, and G. Chu Portrait of transcriptional responses to ultraviolet and ionizing radiation in human cells Nucleic Acids Res 32 2004 4786 4803 (Pubitemid 39429683)
127. A.P. Gasch, M. Huang, S. Metzner, D. Botstein, S.J. Elledge, and P.O. Brown Genomic expression responses to DNA-damaging agents and the regulatory role of the yeast ATR homolog Mec1p Mol Biol Cell 12 2001 2987 3003 (Pubitemid 33062956)
128. J. Fan, X. Yang, W. Wang, W.H. Wood 3rd, K.G. Becker, and M. Gorospe Global analysis of stress-regulated mRNA turnover by using cDNA arrays Proc Natl Acad Sci U S A 99 2002 10611 10616
129. K. Abdelmohsen, Y. Kuwano, H.H. Kim, and M. Gorospe Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence Biol Chem 389 2008 243 255 (Pubitemid 351329020)
130. B.M. Lunde, C. Moore, and G. Varani RNA-binding proteins: modular design for efficient function Nat Rev Mol Cell Biol 8 2007 479 490 (Pubitemid 46809150)
131. K. Mazan-Mamczarz, S. Galban, I. Lopez de Silanes, J.L. Martindale, U. Atasoy, and J.D. Keene RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation Proc Natl Acad Sci U S A 100 2003 8354 8359 (Pubitemid 36842549)
132. W. Wang, H. Furneaux, H. Cheng, M.C. Caldwell, D. Hutter, and Y. Liu HuR regulates p21 mRNA stabilization by UV light Mol Cell Biol 20 2000 760 769 (Pubitemid 30044212)
133. S. Matsuoka, B.A. Ballif, A. Smogorzewska, E.R. McDonald 3rd, K.E. Hurov, and J. Luo ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage Science 316 2007 1160 1166 (Pubitemid 46877472)
134. R.D. Paulsen, D.V. Soni, R. Wollman, A.T. Hahn, M.C. Yee, and A. Guan A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability Mol Cell 35 2009 228 239
135. K.E. Hurov, C. Cotta-Ramusino, and S.J. Elledge A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability Genes Dev 24 2010 1939 1950
136. J. Hildesheim, D.V. Bulavin, M.R. Anver, W.G. Alvord, M.C. Hollander, and L. Vardanian Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53 Cancer Res 62 2002 7305 7315 (Pubitemid 36025254)
137. X.W. Wang, Q. Zhan, J.D. Coursen, M.A. Khan, H.U. Kontny, and L. Yu GADD45 induction of a G2/M cell cycle checkpoint Proc Natl Acad Sci U S A 96 1999 3706 3711 (Pubitemid 29168974)
138. J. Jackman, I. Alamo Jr., and A.J. Fornace Jr. Genotoxic stress confers preferential and coordinate messenger RNA stability on the five gadd genes Cancer Res 54 1994 5656 5662 (Pubitemid 24346263)
139. A. Lal, K. Abdelmohsen, R. Pullmann, T. Kawai, S. Galban, and X. Yang Posttranscriptional derepression of GADD45alpha by genotoxic stress Mol Cell 22 2006 117 128
140. S. Rousseau, N. Morrice, M. Peggie, D.G. Campbell, M. Gaestel, and P. Cohen Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs EMBO J 21 2002 6505 6514 (Pubitemid 35448428)
141. H.C. Reinhardt, I.G. Cannell, S. Morandell, and M.B. Yaffe Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? Cell Cycle 10 2011 23 27
142. R. Brosh, and V. Rotter When mutants gain new powers: news from the mutant p53 field Nat Rev Cancer 9 2009 701 713
143. F. Guo, and Y. Zheng Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion Oncogene 23 2004 5577 5585 (Pubitemid 39093035)
144. S. Mizuarai, K. Yamanaka, and H. Kotani Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells Cancer Res 66 2006 6319 6326
145. J. Luo, M.J. Emanuele, D. Li, C.J. Creighton, M.R. Schlabach, and T.F. Westbrook A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
146. C. Scholl, S. Frohling, I.F. Dunn, A.C. Schinzel, D.A. Barbie, and S.Y. Kim Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834